PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. The company was founded in 2002 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone713-842-1249
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$750,000.00
Profitability
Miscellaneous
Employees12
Next Earnings Date5/10/2019 (Estimated)
OptionableNot Optionable
PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions
What is PLx Pharma's stock symbol?
PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."
How were PLx Pharma's earnings last quarter?
PLx Pharma Inc (NASDAQ:PLXP) announced its quarterly earnings results on Friday, March, 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06. The biotechnology company had revenue of $0.29 million for the quarter. PLx Pharma had a net margin of 1.09% and a negative return on equity of 186.01%. View PLx Pharma's Earnings History.
When is PLx Pharma's next earnings date?
What price target have analysts set for PLXP?
3 analysts have issued 12 month price objectives for PLx Pharma's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate PLx Pharma's stock price to reach $14.00 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Price Targets for PLx Pharma.
What is the consensus analysts' recommendation for PLx Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PLx Pharma.
Has PLx Pharma been receiving favorable news coverage?
News headlines about PLXP stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PLx Pharma earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of PLx Pharma's key competitors?
Some companies that are related to PLx Pharma include REDHILL BIOPHAR/S (RDHL), TAIWAN LIPOSOME/S (TLC), Paratek Pharmaceuticals (PRTK), VBI Vaccines (VBIV), Menlo Therapeutics (MNLO), Nature's Sunshine Products (NATR), Aratana Therapeutics (PETX), Galmed Pharmaceuticals (GLMD), ProMetic Life Sciences (PFSCF), BELLUS Health (BLUSF), Ocular Therapeutix (OCUL), Axovant Sciences (AXON), PhaseBio Pharmaceuticals (PHAS), Cue Biopharma (CUE) and Humanigen (HGEN).
What other stocks do shareholders of PLx Pharma own?
Who are PLx Pharma's key executives?
PLx Pharma's management team includes the folowing people:
- Mr. Michael J. Valentino, Exec. Chairman (Age 65)
- Ms. Natasha Giordano, CEO, Pres & Director (Age 59)
- Mr. Gary L. Mossman, Sr. Advisor (Age 78)
- Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 66)
- Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 51)
When did PLx Pharma IPO?
(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.
Who are PLx Pharma's major shareholders?
PLx Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (16.84%), Harel Insurance Investments & Financial Services Ltd. (2.86%) and Millennium Management LLC (0.65%). Company insiders that own PLx Pharma stock include David Emerson Jorden, Gary L Mossman, Michael J Valentino and Park West Asset Management Llc. View Institutional Ownership Trends for PLx Pharma.
Which major investors are selling PLx Pharma stock?
Which major investors are buying PLx Pharma stock?
PLXP stock was bought by a variety of institutional investors in the last quarter, including Park West Asset Management LLC. Company insiders that have bought PLx Pharma stock in the last two years include David Emerson Jorden, Gary L Mossman, Michael J Valentino and Park West Asset Management Llc. View Insider Buying and Selling for PLx Pharma.
How do I buy shares of PLx Pharma?
Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PLx Pharma's stock price today?
One share of PLXP stock can currently be purchased for approximately $5.60.
How big of a company is PLx Pharma?
PLx Pharma has a market capitalization of $49.01 million and generates $750,000.00 in revenue each year. The biotechnology company earns $900,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. PLx Pharma employs 12 workers across the globe.
What is PLx Pharma's official website?
How can I contact PLx Pharma?
PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]
MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
